Effect of pentoxifylline on multiple sclerosis treatment

Investigating the effects of Pentoxifylline on reduction of relapse frequency in patients with relapsing-remitting multiple sclerosis (RRMS)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201301148430N7

Enrollment

Registered

2014-02-25

Start date

2012-06-30

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

MULTIPLE SCLEROSIS. Multiple sclerosis

Interventions

Intervention 1: intervention group : tablet Pentoxifylline 800 mg daily for 2 months. Intervention 2: control group: placebo with similar dose of intervention group.

Treatment - Drugs

intervention group : tablet Pentoxifylline 800 mg daily for 2 months

control group: placebo with similar dose of intervention group

Eligibility

Sex/Gender

All

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: new case of MS compatible with MC donalds ?relapsing -remitting pattern ? age between 20-40 Y/O exclusion criteria: other patterns of MS except RRMS? other immunomodulatory medications use except beta interferon?pregnancy and lactation ?concurrent autoimmune diseases and it's related drugs?allergy to drug ?liver disease?renal disease ?antihypertensive and ASA and anticoagolant drugs

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Recurrence. Timepoint: monthly. Method of measurement: clinical examination.;Expanded Disability Status Scale. Timepoint: before of the treatment, 6 months after and at the end of the treatment. Method of measurement: clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactakbar hamzei moghaddam MD

kerman university of medical science

shafahospital@kmu.ac.ir+98 34121157809

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026